# Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis

> **NCT05999955** · NA · COMPLETED · sponsor: **Huro Biotech Joint Stock Company** · enrollment: 60 (actual)

## Conditions studied

- Rhinosinusitis
- Rhinitis

## Interventions

- **DRUG:** Neomycin/ Dexameythasone/Xylometazoline
- **COMBINATION_PRODUCT:** Bacillus subtilis DSM32444

## Key facts

- **NCT ID:** NCT05999955
- **Lead sponsor:** Huro Biotech Joint Stock Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-29
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-05-25
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05999955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05999955, "Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05999955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*